Company Details
| Name: |
G1 Therapeutics, Inc. |
| Jurisdiction: |
Alaska |
| Legal type: |
Business Corporation |
| Status: |
Good Standing
|
| Date of registration: |
01 Sep 2021 (3 years ago)
|
| Entity Number: |
10172698 |
| Place of Formation: |
NORTH CAROLINA |
| Address: |
700 PARK OFFICES DRIVE, SUITE 200, RESEARCH TRIANGLE PARK, NC 27709 |
| Mailing Address: |
P.O. BOX 110341, RESEARCH TRIANGLE PARK, NC 27709 |
Officers
| Name |
Role |
|
Mark Velleca, M.D., Ph.D.
|
Director
|
|
MedImmune Ventures, Inc.
|
Shareholder
|
|
BlackRock Institutional Trust Company, N.A.
|
Shareholder
|
|
Glenn P. Muir
|
Director
|
|
Alicia Secor
|
Director
|
|
The Vanguard Group, Inc.
|
Shareholder
|
|
John Bailey Jr.
|
Director
|
|
John Bailey Jr.
|
President
|
|
Jennifer Moses
|
Treasurer
|
|
Garry Nicholson
|
Director
|
|
Eshelman Ventures LLC
|
Shareholder
|
|
Cynthia Flowers
|
Director
|
|
Jacks Lee
|
Director
|
|
Norman Sharpless
|
Director
|
|
Fisher Investments
|
Shareholder
|
|
State Street Global Advisors (US)
|
Shareholder
|
|
James Stillman Hanson
|
Secretary
|
|
Corporation Service Company
|
Registered Agent
|
Professional Licenses
| License Number |
Program |
Type |
Status |
Issue Date |
Effective Date |
Expiration Date |
|
179265
|
Pharmacy
|
Manufacturer
|
Active
|
2021-06-03
|
2024-05-31
|
2026-06-30
|
Date of last update: 23 Jan 2025
Sources:
State of Alaska - Department of Commerce, Community, and Economic Development
